Cumberland Partners Ltd Purchases 1,545 Shares of AbbVie Inc. $ABBV

Cumberland Partners Ltd increased its holdings in AbbVie Inc. (NYSE:ABBV) by 6.6% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 25,102 shares of the company’s stock after buying an additional 1,545 shares during the period. Cumberland Partners Ltd’s holdings in AbbVie were worth $4,659,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ABBV. Marshall & Sullivan Inc. WA bought a new position in shares of AbbVie in the second quarter worth approximately $25,000. TD Capital Management LLC raised its position in shares of AbbVie by 82.9% during the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after buying an additional 58 shares in the last quarter. Spurstone Advisory Services LLC bought a new stake in shares of AbbVie during the 2nd quarter worth $28,000. Financial Gravity Companies Inc. purchased a new position in AbbVie in the second quarter worth $36,000. Finally, Bear Mountain Capital Inc. increased its position in shares of AbbVie by 480.6% during the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after purchasing an additional 173 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ABBV. HSBC set a $225.00 target price on AbbVie in a research report on Thursday, October 2nd. JPMorgan Chase & Co. boosted their price objective on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Guggenheim lifted their target price on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. Raymond James Financial set a $256.00 price target on shares of AbbVie in a research report on Monday, November 3rd. Finally, DZ Bank downgraded AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective on the stock. in a report on Tuesday, November 4th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $240.14.

AbbVie Price Performance

ABBV stock opened at $233.13 on Thursday. The stock has a market capitalization of $412.04 billion, a price-to-earnings ratio of 111.02, a PEG ratio of 1.42 and a beta of 0.50. The firm’s 50-day moving average price is $226.27 and its two-hundred day moving average price is $204.77. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period last year, the firm earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is presently 524.24%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.